Overall, women with more advanced MS disability had similar peripartum relapse activity as those with less disability, ...

For decades, multiple sclerosis (MS) research has focused largely on the inflammatory lesions visible on MRI scans. Yet new ...

The U.S. Food and Drug Administration is delaying by three months its decision on whether or not to approve tolebrutinib for ...

Patients with primary progressive MS more commonly exhibited delays in overall disability progression following treatment with ocrelizumab vs placebo.

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

The earliest symptoms of multiple sclerosis (MS) can come and go, which makes them easy to ignore — and makes diagnosing this common neurological disease complicated. That’s why it’s so important to ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...

Please provide your email address to receive an email when new articles are posted on . A study examined the effects of exercise in 3,000 patients with MS for up to 15 years. More physical activity ...

Understanding how MS can impact your income, insurance, disability benefits, and budgeting allows you to plan ahead with ...

A new study conducted by researchers from the Corrine Goldsmith Dickinson Center for Multiple Sclerosis at Icahn School of Medicine at Mount Sinai in collaboration with Novartis, the University of ...